Close Menu

NEW YORK – Sports organizations and paramedics need effective diagnostic tests that they can use at the point of care to decide quickly how to respond to a suspected concussion.

To address this need, Medicortex Finland is developing a diagnostic testing platform that uses an undisclosed glycan molecule marker whose levels were elevated in testing samples from brain-injury patients during two clinical studies, according to the firm's CEO Adrian Harel.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.